FORTRESS BIOTECH INC

NASDAQ: FBIO (Fortress Biotech, Inc.)

最近更新时间: 1小时之前

1.54

-0.02 (-1.28%)

前收盘价格 1.56
收盘价格 1.60
成交量 183,079
平均成交量 (3个月) 359,083
市值 42,511,544
价格/销量 (P/S) 0.460
股市价格/股市净资产 (P/B) 2.22
52周波幅
1.36 (-11%) — 2.89 (87%)
利润日期 13 May 2025 - 19 May 2025
营业毛利率 -59.52%
营业利益率 (TTM) -151.04%
稀释每股收益 (EPS TTM) -2.96
季度收入增长率 (YOY) -7.10%
流动比率 (MRQ) 1.23
营业现金流 (OCF TTM) -102.22 M
杠杆自由现金流 (LFCF TTM) -56.57 M
资产报酬率 (ROA TTM) -38.05%
股东权益报酬率 (ROE TTM) -1,739.64%

市场趋势

短期 中期
行业 Biotechnology (US) 混合的 混合的
Biotechnology (全球的) 混合的 混合的
股票 Fortress Biotech, Inc. 看跌 看涨

AIStockmoo 评分

0.1
分析师共识 1.5
内部交易活动 1.5
价格波动 0.5
技术平均移动指标 -2.5
技术振荡指标 -0.5
平均 0.10

相关股票

股票 市值 DY P/E(TTM) P/B
FBIO 43 M - - 2.22
CGON 2 B - - 3.75
CGEM 469 M - - 0.820
OMER 458 M - - 8.44
ORIC 437 M - - 2.19
ZVRA 396 M - - 10.21

Fortress Biotech Inc is a biopharmaceutical company. The firm is involved in the business of acquiring, developing, and commercializing pharmaceutical and biotechnology products. Its product portfolio encompasses Qbrexza, Accutane, Amzeeq, Zilxi, Targadox, Ximino, and Exelderm. The business activities of the group are functioned through Dermatology Product Sales, and Pharmaceutical and Biotechnology Product Development. It derives the majority of its revenues from Dermatology segment. Its subsidiaries also operate in biotechnology, pharmaceutical, oncology, therapeutics sectors.

部门 Healthcare
行业 Biotechnology
投资方式 Small Value
内部持股比例 27.70%
机构持股比例 17.36%

所有权

姓名 日期 持有股份
Kestra Advisory Services, Llc 31 Dec 2024 226,231
Hb Wealth Management, Llc 31 Dec 2024 106,850
52周波幅
1.36 (-11%) — 2.89 (87%)
16.00 (938.96%)
总计 1 购买
公司 日期 目标价格 调整类型 价格@调整类型
Roth MKM 11 Mar 2025 16.00 (938.96%) 购买 1.73
名称 平均购买 ($) 平均卖出 ($) 总净额 总净值 ($)
JIN DAVID 1.54 - 5,000 7,700
累积净数量 5,000
累积净值 ($) 7,700
累积平均购买 ($) 1.54
累积平均卖出 ($) -
名称 持有人 日期 类型 数量 价格 价值 ($)
JIN DAVID 职员 01 Apr 2025 获得 (+) 5,000 1.54 7,700
日期 类型 细节
01 Apr 2025 公告 Journey Medical Corporation Appoints Ramsey Alloush as Chief Operating Officer
31 Mar 2025 公告 Fortress Biotech Reports 2024 Financial Results and Recent Corporate Highlights
28 Mar 2025 公告 Checkpoint Therapeutics Reports Full-Year 2024 Financial Results and Recent Corporate Updates
26 Mar 2025 公告 Journey Medical Corporation Reports Full-Year 2024 Financial Results and Recent Corporate Highlights
24 Mar 2025 公告 Journey Medical Corporation Launches Emrosi™ (40 mg Minocycline Hydrochloride Modified-Release Capsules, 10 mg immediate release and 30 mg extended release) for the Treatment of Rosacea
19 Mar 2025 公告 Journey Medical Corporation to Announce Year End 2024 Financial Results on March 26, 2025
17 Mar 2025 公告 Partex and Fortress Biotech Announce Strategic Collaboration to Accelerate Asset Identification and Evaluation Using Proprietary AI Platform
12 Mar 2025 公告 Journey Medical Corporation to Participate in the 37th Annual ROTH Conference
09 Mar 2025 公告 Sun Pharma to Acquire Checkpoint Therapeutics
05 Mar 2025 公告 Journey Medical Corporation Announces Publication in the Journal of the American Medical Association - Dermatology of the Phase 3 Clinical Trial Results of Emrosi™ (DFD-29) to Treat Rosacea
05 Mar 2025 公告 Mustang Bio Regains Compliance with Nasdaq Capital Market Requirement
04 Mar 2025 公告 Journey Medical Corporation to Exhibit at the 2025 American Academy of Dermatology Annual Meeting in Orlando, Florida
27 Feb 2025 公告 Mustang Bio Announces Sale of Fixed Assets and Exit of Facility
11 Feb 2025 公告 Mustang Bio Regains Compliance with Nasdaq Minimum Bid Price Requirement
10 Feb 2025 公告 Mustang Bio Announces Closing of $8 Million Public Offering
06 Feb 2025 公告 Mustang Bio Announces Pricing of $8 Million Public Offering
27 Jan 2025 公告 Fortress Biotech Announces First Patient Dosed in Phase 2 Clinical Trial of Triplex Vaccination in Stem Cell Donors to Reduce CMV Events in Recipients of HSCT
23 Jan 2025 公告 Journey Medical Corporation to Host Conference Call to Discuss U.S. Commercial Launch Plan for Emrosi™ (Minocycline Hydrochloride Extended Release Capsules, 40 mg) for the Treatment of Rosacea
14 Jan 2025 公告 Mustang Bio Announces Reverse Stock Split
06 Jan 2025 公告 Sentynl Therapeutics Announces U.S. FDA Acceptance and Priority Review of New Drug Application for CUTX-101 (Copper Histidinate) Product Candidate for Treatment of Menkes Disease
06 Jan 2025 公告 Fortress Biotech and Cyprium Therapeutics Announce U.S. FDA Acceptance and Priority Review of NDA for CUTX-101 for Treatment of Menkes Disease
显示更多

支撑、阻力和趋势线水平是由人工智能(AI)模型生成的,请谨慎解读。

投资组合

AI 建议策略模板

自定义的价格提醒

风险概况

| | | | |
很保守
适度保守
中等
中等风险
激进风险
安全边际 (EP)
部分利润 (TP1)
目标利润 (TP2)
最大损失 (SL)

免责声明:以上内容仅供参考,并非投资建议。请咨询合格的财务顾问。

开始购买价格 (EP)

第一个目标价格赚取利润 (TP1)

第二个目标价格赚取利润 (TP2)

停止损失价格 (SL)

52周波幅范围
 
52WL
 
52WH
SL
EP
TP1
TP2

所有提醒价格都在52周波幅范围内

已实现利润 -
未实现利润 -
收到股息 2025 -
利润总额 -
平均回报 -
数量(购买) -
平均价格(购买) -
数量(卖出) -
平均价格(卖出) -
没有符合您标准的股票